Barclays Capital Kept Aramark Holdings (ARMK) As Equal Weight; Has Target Of $47.00; Neos Therapeutics (NEOS) SI Increased By 5.19%

Among 14 analysts covering Aramark Holdings Corporation (NYSE:ARMK), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Aramark Holdings Corporation has $50.0 highest and $35.0 lowest target. $43.25’s average target is 0.89% above currents $42.87 stock price. Aramark Holdings Corporation had 33 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Buy” rating by RBC Capital Markets given on Tuesday, November 14. Macquarie Research initiated it with “Outperform” rating and $44 target in Friday, August 26 report. The rating was upgraded by Zacks on Wednesday, August 12 to “Sell”. RBC Capital Markets downgraded the shares of ARMK in report on Monday, March 13 to “Outperform” rating. The firm has “Top Pick” rating by RBC Capital Markets given on Friday, November 6. RBC Capital Markets maintained Aramark (NYSE:ARMK) on Monday, June 26 with “Buy” rating. The stock has “Buy” rating by Sterne Agee CRT on Tuesday, March 22. RBC Capital Markets maintained it with “Top Pick” rating and $42 target in Thursday, August 11 report. The rating was maintained by Nomura on Thursday, August 11 with “Buy”. The firm has “Buy” rating given on Monday, September 11 by Robert W. Baird.

Neos Therapeutics Incorporated (NASDAQ:NEOS) had an increase of 5.19% in short interest. NEOS’s SI was 2.44M shares in December as released by FINRA. Its up 5.19% from 2.32M shares previously. With 538,800 avg volume, 5 days are for Neos Therapeutics Incorporated (NASDAQ:NEOS)’s short sellers to cover NEOS’s short positions. The SI to Neos Therapeutics Incorporated’s float is 20.54%. It closed at $9.7 lastly. It is down 9.07% since December 22, 2016 and is uptrending. It has underperformed by 7.63% the S&P500.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has market cap of $281.27 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

Among 7 analysts covering Neos Therapeutics (NASDAQ:NEOS), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Neos Therapeutics had 21 analyst reports since August 17, 2015 according to SRatingsIntel. BMO Capital Markets maintained the shares of NEOS in report on Friday, September 15 with “Buy” rating. The rating was initiated by JMP Securities with “Market Outperform” on Monday, August 17. RBC Capital Markets maintained it with “Outperform” rating and $33 target in Thursday, November 12 report. The stock has “Outperform” rating by Wells Fargo on Friday, February 19. Cantor Fitzgerald maintained it with “Buy” rating and $20.0 target in Wednesday, November 8 report. The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) has “Neutral” rating given on Monday, March 20 by UBS. BMO Capital Markets initiated the stock with “Outperform” rating in Monday, August 17 report. RBC Capital Markets maintained it with “Buy” rating and $12.0 target in Thursday, September 14 report. BMO Capital Markets maintained Neos Therapeutics, Inc. (NASDAQ:NEOS) rating on Thursday, October 26. BMO Capital Markets has “Buy” rating and $14.0 target. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, June 29.

The stock decreased 0.03% or $0.01 during the last trading session, reaching $42.87. About 188,794 shares traded. Aramark (NYSE:ARMK) has risen 13.66% since December 22, 2016 and is uptrending. It has underperformed by 3.04% the S&P500.

Aramark provides food, facilities, and uniform services to education, healthcare, business and industry, sports, leisure, and corrections clients in North America and internationally. The company has market cap of $10.50 billion. It offers managed services include dining, catering, food service management, convenience-oriented retail operations, grounds and facilities maintenance, custodial, energy and construction management, and capital project management. It has a 28.77 P/E ratio. The firm also provides non-clinical support services, such as patient food and nutrition, and retail food services; and facilities services comprising clinical equipment maintenance, environmental, laundry and linen distribution, plant operations, strategic/technical, energy and supply chain management, purchasing, and central transportation.

Investors sentiment decreased to 0.84 in Q3 2017. Its down 0.38, from 1.22 in 2017Q2. It fall, as 32 investors sold Aramark shares while 104 reduced holdings. 29 funds opened positions while 85 raised stakes. 228.50 million shares or 0.02% more from 228.44 million shares in 2017Q2 were reported. Dekabank Deutsche Girozentrale has invested 0.04% of its portfolio in Aramark (NYSE:ARMK). Fuller And Thaler Asset accumulated 1,800 shares. Amp Cap Investors accumulated 0.01% or 61,487 shares. Caisse De Depot Et Placement Du Quebec owns 12,735 shares for 0% of their portfolio. Pitcairn holds 7,642 shares or 0.04% of its portfolio. Asset One Ltd has 0.03% invested in Aramark (NYSE:ARMK) for 359,754 shares. Invesco Ltd accumulated 0% or 91,169 shares. New York-based Cornerstone Mgmt Llc has invested 0.03% in Aramark (NYSE:ARMK). The North Carolina-based Sterling Ltd Liability Co has invested 0.04% in Aramark (NYSE:ARMK). Three Peaks Capital Management Limited Liability Co owns 400,971 shares or 2.4% of their US portfolio. Guardian Cap Limited Partnership stated it has 9,313 shares. Meiji Yasuda Life Ins Company accumulated 40,790 shares. Pnc Fincl Grp Incorporated Incorporated, Pennsylvania-based fund reported 41,344 shares. Cap Rech Global holds 19.22M shares. Los Angeles Capital Mgmt And Equity Rech holds 224,848 shares or 0.05% of its portfolio.